Alessandro Ottaiano

Via M. Semmola
Naples, 80131, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.

Interpreting cancer genetics through a two-step "evolutionary cascade hypothesis": bridging neutral and selective perspectives.

Journal: Journal of translational medicine

Published: January 06, 2026

A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas.

A systematic review and meta-analysis of pazopanib efficacy and adverse effects in sarcomas.

Journal: Journal of translational medicine

Published: December 09, 2025

Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.

Tumor mutational burden modulates the prognostic effect of RAS mutations in metastatic colon cancer: mechanistic insights and genotype-phenotype correlations.

Journal: Journal of translational medicine

Published: September 05, 2025

Correction To: High tumor mutational burden assessed through next‑generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

Correction To: High tumor mutational burden assessed through next‑generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

Journal: Journal of translational medicine

Published: January 08, 2025

High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

High tumor mutational burden assessed through next-generation sequencing predicts favorable survival in microsatellite stable metastatic colon cancer patients.

Journal: Journal of translational medicine

Published: October 09, 2024

Clinical and genetic drivers of oligo-metastatic disease in colon cancer.

Clinical and genetic drivers of oligo-metastatic disease in colon cancer.

Journal: Neoplasia (New York, N.Y.)

Published: August 06, 2024

Adipokines as potential pharmacological targets for immune inflammatory rheumatic diseases: Focus on rheumatoid arthritis, osteoarthritis, and intervertebral disc degeneration.

Adipokines as potential pharmacological targets for immune inflammatory rheumatic diseases: Focus on rheumatoid arthritis, osteoarthritis, and intervertebral disc degeneration.

Journal: Pharmacological research

Published: April 02, 2024

Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.

Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine/tipiracil (TAS-102) treatment.

Journal: Journal of translational medicine

Published: March 15, 2024

Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments.

Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments.

Journal: Molecular and cellular probes

Published: December 13, 2023

Revolutionizing KRAS p.G12C therapy in metastatic colorectal cancer: The triumph of dual inhibition.

Revolutionizing KRAS p.G12C therapy in metastatic colorectal cancer: The triumph of dual inhibition.

Journal: Med (New York, N.Y.)

Published: October 27, 2023

The Italian experience with the use of monitoring registers attached to negotiated agreements (MEAs) of the Italian Medicines Agency is a tool for governance and clinical appropriateness.

The Italian experience with the use of monitoring registers attached to negotiated agreements (MEAs) of the Italian Medicines Agency is a tool for governance and clinical appropriateness.

Journal: Journal of cancer policy

Published: August 17, 2023

BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer.

BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer.

Journal: Neoplasia (New York, N.Y.)

Published: July 26, 2023

Showing 1-12 of 18

Last Updated: 09/26/2026